Paul Chaplin, Bavarian Nordic CEO
September 20, 2022 01:18 PM EDTUpdated 02:52 PM
Pharma
Manufacturing

Bavar­i­an Nordic inks an­oth­er ma­jor vac­cine con­tract with Cana­da

Tyler Patchen

News Reporter

As mon­key­pox cas­es con­tin­ue to af­fect na­tions in North Amer­i­ca and across the globe, Cana­da is look­ing to step up its pre­ven­tion ef­forts via a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

Com­pass Path­ways de­lays key Phase 3 psilo­cy­bin read­outs, spurring 30% lay­offs

A service from the Financial Times